Diego Sadler, MD

Appointed
2015

Additional Training

• TEACHING ACTIVITIES:

  Instructor of Medicine, teaching internal medicine residents and students, University of Massachusetts, Worcester, MA 1995-1997
• Teaching rounds and lectures, internal medicine residents JFK Medical Center, Lake Worth, FL. 2007-2012
• Teaching rounds cardiology fellows, JFK Medical Center, Lake Worth, FL 2012-2015
• Cardio Oncology teaching for staff, nurses, residents Cleveland Clinic Florida, Weston, FL 2016-present
• Cardio Oncology Grand Rounds Internal Medicine, Cardiology and Oncology: Cleveland Clinic Florida, Weston, FL 2017-2020
• Inpatient teaching rounds Cardiology Service with medical students, residents and cardiology fellows, Cleveland Clinic Florida, Weston, FL 2020-present
• Preceptorship of Oncology Research fellows’ rotation in Cardio Oncology. Cleveland Clinic Florida, Weston, FL 2020, 2021.
• Supervision cardiology research fellow in cardio-oncology. Cleveland Clinic Florida, Weston, FL 2021-present.

  INVITED LECTURES:

  Speaker/panelist: American College of Cardiology: CV care of the cancer patient. February 2022. How to start and sustain a cardio-oncology program. February 2022
• Invited speaker: Cardiovascular effects of immune check point inhibitors. Current knowledge and future perspectives. Ecuadorian Society of Cardiology. November 2021
• Speaker and panelist: American College of Cardiology, California Chapter July 2021: “How to start and grow a Cardio-Oncology Program”
• Featured Invited Faculty Speaker Argentine Society of Cardiology Cardio-Oncology Symposium August 2021: Past, present and future of Cardio Oncology
• Speaker: International Cardio Oncology Society Webinar: Impact of COVID-19 Pandemic in Cardio Oncology practice. September 2020
• Speaker: Argentine Society of Cardiology (SAC) 49th Congress (virtual): “How to establish a Cardio Oncology Program” (lecture), and speaker/panelist on “Practice tips in Cardio oncology”.
• Invited speaker: State of Cardio Oncology in the World. 3rd International Argentine Symposium in Cardio Oncology (virtual), September 2020
• Session Co-Chair: towards a comprehensive cardiac-cancer care International Symposium by Israel Society of Cardio Oncology (Virtual) January 2021
• American College of Cardiology: CV care of the Cancer patient: Faculty presentation on multi state project. Washington DC, January 2020
• SAC 2019: three presentations in Cardio Oncology: 50th Argentine Congress of Cardiology. Buenos Aires, October 2019.
• Cardiovascular effects of Immunotherapy. September 2019 Cardiology Congress of Panama
• Breast Cancer management for cardiovascular specialists. September 2019 Cardiology Congress of Panama.
• Breast Cancer and Heart Disease: speaker at Florida ACC Chapter Winter meeting, Orlando, FL January 2019.
• Cardio Oncology INCOR cardiovascular Imaging Congress, Lima, Peru, September 2018
• Cardio Oncology and Strain Imaging presentations, Cleveland Clinic Diastology and Structural Heart disease national conference, Ft, Lauderdale, March 2018
• Cardio Oncology presentations in Guatemala Cardiovascular Conference, April 2018.
• Grand Rounds in Cardio Oncology. Cleveland Clinic Florida July 2016, 2018, 2019.
• Oncology Board Rounds in Cardio Oncology, Good Samaritan Med Center, WPB, August 2016
• Cardio Oncology Grand Rounds, Indian River Medical Center, October 2017.

  Poster presentations:

  Global Cardio Oncology Registry: structure for a multinational collaboration. American Heart Association November 2021
• Starting and Sustaining a Cardio Oncology Program: Practical Model to Succeed Utilizing Existing Resources at your institution, “Advancing the Cardiovascular Care of the Oncology patient”, ACC, Washington DC, January 2019
• Cardio Oncology awareness among Cardiologists and Oncologists in Florida: Survey from the Florida Chapters of the American College of Cardiology (ACC) and American Society of Clinical Oncology (ASCO) Work Group. Global Cardio Oncology Summit 2019, Sao Paulo Brazil, October 2019.
• Starting a Cardio Oncology Program: a simple approach for rapid Growth”. Global Cardio-Oncology Summit 2018, Tampa, FL, September 2018.
• "Effects of diabetes with or without hypertension in the genesis of left ventricular hypertrophy in the rat." 45th Annual Scientific Session. American College of Cardiology. Orlando (Fla), March 1996.
• "Hypertensives with concentric remodeling have depressed chamber, pump and myocardial function in the absence of left ventricular hypertrophy." 68th Annual Scientific Sessions of the American Heart Association. Anaheim, California. November 1995.
• "Role of Transesophageal echocardiography in the assessment of non-hemorrhagic stroke". 15th Congress of the European Society of Cardiology. Nice, France. September 1993.
• "Is computed tomography useful in identifying stroke patients with a positive transesophageal
• Echocardiography study?" 65th Annual Scientific Sessions of the American Heart Association. New Orleans, Louisiana. November 1992.
• "Is transesophageal echocardiography useful in the routine assessment of patients after non-hemorrhagic cerebrovascular events". Third Annual Scientific Sessions. American Society of Echocardiography. Boston, Massachusetts. June 1992.
• "Left and right ventricular diastolic filling indexes in systemic hypertension: relationship to left ventricular mass". Seventh scientific meeting of The American Society of Hypertension. New York, NY. May 1992.
• "Left atrial thrombi in non-rheumatic atrial fibrillation: Assessment of prevalence by transesophageal echocardiography". 64th Annual Scientific Sessions of the American Heart Association. Anaheim, California. November 1991.
• "Left Ventricular mass-diastolic filling abnormalities relationship in systemic hypertension". XIII Congress of the European Society of Cardiology. Amsterdam, the Netherlands. August 1991.
• "Impact of hemodialysis on left and right ventricular Doppler diastolic filling indices". Annual Scientific Sessions. American Federation for Clinical Research. Seattle, WA. May 1991.
• "Detection of intra-cardiac source of embolism by transesophageal echocardiography in stroke patients". 40th Annual Scientific Session. American College of Cardiology. Atlanta, Ga. March 1991.phy

  BIBLIOGRAPHY:

  1. Sadler D, Chaugalian C, Cubeddu R, Stone E, Samuel T, et al. Practical and Cost effective Model to build and sustain a Cardio-Oncology Program. Cardio Oncology Journal. 2020 https://doi.org/10.1186/s40959-020-00063-x (doi: 10.1186/s40959-020-00063-x)
  2. Sadler D, Fradley M, Ismail Khan R, Raez L, Bhandare D, Elson L, Perloff D, et al. Florida Inter-Specialty Collaborative Project to improve Cardio Oncology Awareness and Identify Existing Gaps. JACC Cardio Onc Sept 2020, 2 (3) 535-538
  3. Sadler D, DeCara J, Herrmann J, Arnold A, Ghosh A,Abdel-Quadir H, Yang E, Smith S, Ahter N, Leja M, Carvalho Silva C, Raikhelkar J, Brown SA, Dent S, O’Quinn R, Thuny F, Moudgil R, Raez L, Okwuosa T, Daniele A, Bauer B, Kondapalli L,Ismail-Khan R, Lax J, Blaes A, Nahleh Z, Elson L, Baldassarre L, Zaha V, Rao V, Sierra Lara D, Skurka K. COVID-19 Pandemic and its impact on Cardio Oncology: Results from the COVID-19 International Collaborative Network Survey. Cardio Oncology Journal. November 2020. 6 (28)
  4. Sadler D, Arnold A, Herrmann J, et al. Reaching across the Aisle. Cardio Oncology Advocacy and Program Building. Current Oncology Reports. April 2021. (2021) 23:64 https://doi.org/10.1007/s11912-021-01059-1
  5. Scuchan BS, Elson L, Alley E, Leung K, Lewis Camargo A, Eliminian E, Sadler D. Checkpoint inhibitor-
  induced myocarditis and myasthenia gravis in a recurrent metastatic thymic carcinoma patient. European Heart Journal CR (4):3 June 2020. 1-8. https://doi.org/10.1093/ehjcr/ytaa051
  6. Bilani, N, Elson L, Alley E, Eliminan E, Sadler D. A Multimodal Approach to Evaluate for Cardiac Metastasis in a Case of Non-Small Cell Lung Cancer. CR Case Rep Oncol 2020;13:212-218. doi: 10.1159/000505534
  7. Kwan J, Henry M, Christophers B, Sadler D, Cheng R, Purwani P, Dent S, Fradley M, Brown SA. The role and impact of social media in Cardio-Oncology During the COVID-19 pandemic. Current Oncology Reports. July 2021 (2021) 23:99 https://doi.org/10.1007/s11912-021-01081-3
  8. Sadler D: Book Chapter. Atlas of imaging in Cardio Oncology. Chapter Cardio Oncology in the Community. September 2021. Atlashttps://www.springer.com/978-3-030-70997-6 DOI 978-3-030-70998-3_30, © 2021
  9. Sadler D, Moudgil R, Teske A, Collier P, Sarkar A, Barac A, Brown SA, Herrmann J. Global Cardio Oncology Registry: structure for a multinational collaboration. Circulation 2021;144A 11675
  10. Sadler D, Aurigemma GP, Reda D, Williams DW, Gottdiener JS. Systolic function is depressed in hypertensive men with concentric remodeling. Hypertension 1997; 30:777-81.
  11. Sadler D, Chung E, Meyer T, Rossini A, Gaasch WH, Aurigemma GP. Effects of diabetes with or without hypertension in the genesis of left ventricular hypertrophy in the rat. J Amer Coll Cardiol 1996; 27: 35 A
  12. Klein AL, Carneiro M, Murray D, Pape L, Sadler D, Grimm R, Stewart WJ, Thomas JD. Influence of mitral regurgitation and left ventricular systolic dysfunction on pulmonary venous flow in patients with atrial arrhythmias. A Doppler TEE study of 110 patients.
  J Amer Coll Cardiol 1996; 27: 349 A
  13. Sadler D, Aurigemma GP, Williams DW, Reda D, Gottdiener JS, Materson B. Hypertensives with concentric remodeling have depressed chamber, pump and myocardial function in the absence of left ventricular hypertrophy. Circulation 1995; 92 : Suppl I-268.
  14. Aurigemma GP, Sharma M, Sadler D, Meyer TE, Gaasch WH. Extent and velocity of shortening provide similar information about chamber and myocardial function in hypertrophic and normal hearts. Circulation 1995; 92 : Suppl I-668.
  14. Aurigemma GP, Chung ES, Sadler D, Gaasch WH, Meyer T. Left ventricular geometry, systolic function, and adrenergic responsiveness in rats with pressure overload hypertrophy. Circulation 1995; 92 : Suppl I-668.
  15. Meyer TE, Chung E, Dobson J, Aurigemma GP, Sadler D, Gaasch WH. Adenosine uptake blockade accelerates the transition from compensated to decompensated left ventricular hypertrophy. Circulation 1995; 92 : Suppl I-26.
  16. Sherzoy A, Sadler D, Brown J. Cocaine-related acute aortic dissection diagnosed by transesophageal echocardiography. Am Heart J 1994; 4 : 841-43.
  17. Brown J, Sadler D. Assessment of left atrial thrombi in non rheumatic atrial fibrillation. A transesophageal echocardiography study. Int J Card Imag 1993 ; 9 : 65-72.
  18. Sadler D, Brown J, Sherzoy A. Role of transesophageal echocardiography in the assessment of non-hemorrhagic stroke. Eur Heart J 1993 ; 14 :A 436
  19. Brown J, Sadler D.Transesophageal Echocardiography. Developments in Cardiol 1992; 2 : -15.
  20. Sadler D, Brown J, Nurse H, Roberts J: Impact of hemodialysis on Left and Right Ventricular Doppler Diastolic Filling Indices. Am J Med Sci 1992; 304 (2): 83-90.
  21. Sadler D, Brown J, McCleary M, Stein J: Is Computed Tomography useful in identifying stroke patients with a positive transesophageal echocardiographic study? Circulation 1992; 86 : I-147
  22. Sadler D, Brown J, Branche G, Streets M, Roberts J. Left and right ventricular diastolic filling indexes in systemic hypertension: relationship to left ventricular mass. Am J Hypert 1992; 5 : 27 A.
  23. Sadler D, Brown J, Prothro D. Is transesophageal echocardiography useful in the routine assessment of patients after non-hemorrhagic events?. J Am Soc Echocardiography 1992 ; 5:308.
  24. Sadler D, Brown J, Branche G, Streets M, Roberts J.Left Ventricular mass-diastolic filling abnormalities relationship in systemic hypertension. Eur Heart J 1991;12 Suppl A: 58.
  25. Sadler D, Brown J, Islam M, Patel P, Prothro D. Left atrial thrombi in non-rheumatic atrial fibrillation: Assessment of prevalence by transesophageal echocardiography. Circulation 1991; Suppl II-693.
  26. Sadler D, Brown J, Chandrashekar PS, Shafer S. Detection of intracardiac source of embolism by transesophageal echocardiography in stroke patients. J Amer Coll Cardiol 1991; 17 : 315 A.
  27. Sadler D, Brown J, Nurse H, Francis CK. Impact of hemodialysis on left and right ventricular Doppler diastolic filling indices. Clin Res 1991; 39 : 233 A.
  28. Shaukat M, Sadler D, Hoffman RA, Johnson J, Sackner MA. Thoracocardiography: A non-invasive means to assess cardiac loading. Am Rev Resp Dis 1990 ; 141: A 576.
  29. Sadler D, Staszewsky L, Ortiz J, Paviotti C, Bazzino O. 2-D Echocardiogram in Acute Myocardial Infarction: Prognostic value for the first year of follow up. Rev Argent Cardiol 1987; 55 : S 75.
  30. Ortiz J, Sadler D, Staszewsky L, Panza J, Bazzino O. 2-D Echocardiogram in Acute Myocardial Infarction: It's correlation with the Electrocardiogram. Rev Argent Cardiol 1987; 55: S 74.
  31. Trivi M, Bazzino O, Arenzo J, Sadler D. Silent and symptomatic Ischemia in Unstable Angina. Rev Argent

Professional Highlights

• Head, Cardio Oncology section, Cleveland Clinic Florida 2016-present
• President Elect Medical Staff, JFK Hospital, 2012-2013
• Chief of Staff, JFK Medical Center, 2014- 2015.
• Credentials Committee Chairman, JFK Hospital, 2012-2013
• Medical Executive Committee, JFK Hospital, 2004-2005, 2012-Present
• Board of Trustees, JFK Medical Center, 2012-2015
• Chairman Peer Review JFK Medical Center, 2016-2017
• Cardio-Vascular Co-Management Group, Governance Board member, Good Samaritan Medical Center.2013-2014

  ACADEMIC APPOINTMENTS:

  Clinical Assistant Professor of Cardio-Vascular Medicine.
• Cleveland Clinic Lerner College of Medicine, Case Western Reserve University. 2017-present.
• Associate Professor promotion application approved by CCLCM. Pending CWRU final approval (early 2022)
• Cleveland Clinic Educators Collaborative. January 2020-2024.
• Affiliate Clinical Assistant Professor of Biomedical Sciences, Charles E. Schmidt College of Biomedical Science, Florida Atlantic University, Boca Raton, Florida, 2009-2012.
• Voluntary Assistant Professor of Medicine, Department of Medicine, Leonard M. Miller School of Medicine, University of Miami, Miami, Florida, 2009-2016

Certifications

• Internal Medicine - Cardiovascular Disease

Specialty Interests

Special interest in Cardio Oncology, evaluation of cardiac effects of cancer treatment, effects of chemotherapy and radiation therapy on cardio-vascular system. Preventive cardiovascular care of cancer patients. Cardiovascular follow up of cancer survivors. Cardiac imaging in Cardio Oncology. Cardio oncology as a new subspecialty in Cardio Vascular Medicine.

Awards & Honors

• Honor Degree (Dean’s list), issued by University of Buenos Aires School of Medicine.
• American College of Cardiology Board of Governors: Chapter Section Grant award for Cardio Oncology Education/Advocacy with Florida Chapter and ACC Cardio Oncology Council. January 2019
• American College of Cardiology Florida Chapter: 2020 Distinguished Service Award.
• International Cardio-Oncology Society Center of Excellence Gold status designation (higher designation) 2021-2024

Innovations & Patents

• At the institutional level we started and lead the Cardio-Oncology program at Cleveland Clinic Florida where we established an innovative mechanism with a Cardio Oncology Clinic at the Cancer Center to facilitate interaction and facilitate access to cardiovascular care for oncology patients. This setting improves workflow and encourages inter-specialty consultations and pathways for expedite care and improves patient care. We have grown our program, the only existing in south east Florida, and receive referrals and consultations from state and national centers.

  At the state level, we started and Chair the Cardio Oncology Committee at the American College of Cardiology (ACC) Florida Chapter (3,000 Chapter members) and started a partnership with the American Society of Clinical Oncology (ASCO) Florida Chapter (FLASCO, 3,200 Chapter members). Our successful collaboration program published by the Journal of the American College of Cardiology Cardio-Oncology was a model subsequently adopted by other states. We are working towards starting a Cardio-Oncology state Registry, within the context of the Global Cardio-Oncology Registry that we also lead. We created educational materials for cardiology and oncology practitioners in Florida, available online at the state Chapters websites (ACC and ASCO)

  At the national level, we started a multistate collaborative advocacy network that has now grown into a state, national and international network with cardiologists and oncologists. We are members of the American College of Cardiology Leadership Council for the 2020-2023 term and co-Chair the Advocacy Work Group to improve access to care, improve awareness of cancer and cardiovascular disease in the medical community, and work with government agencies on regulatory issues related to access to expensive medications, and advocate in Congress for legislation for research and public education support.

  At the international level, we participate in the Education Committee of the International Cardio-Oncology Society (ICOS) the international leader in cardio-oncology. To further grow our collaborative model at the state and national level, we developed a large collaborative network that currently has 117 participating hospitals/sites from 23 countries, including many major academic US Centers from 22 states and participants from large academic and community centers from Latin America, Europe, Asia and Australia. We have completed the platform to launch the first Global International Cardio-Oncology Registry to address regional and national differences in delivery of care and outcomes and to evaluate disparities in cardio -oncology care and its impact on outcomes.

Memberships

• Fellow American College of Cardiology (FACC)
• Fellow American College of Physicians (FACP)
• American Society of Nuclear Cardiology
• American College of Cardiology Cardio Oncology Advocacy Work Group
• International Cardio Oncology Society
• American College of Cardiology. Fellow: 1997-present. Leadership: Cardio Oncology Council
• American College of Physicians. Fellow 2010-present
• American Society of Nuclear Cardiology. Member 1997-present
• International Cardio-Oncology Society. Member 2015-present. Leadership: Education Committee.
• American Heart Association. Member, Clinical Council. 2018-present
• Palm Beach County Medical Society. Member 1998-present

  PROFESSIONAL SERVICES:

  Manuscript reviewer:
• Journal of the American College of Cardiology Cardio Oncology: 2019-present
• Cardio Oncology Journal: 2019-present
• Breast Cancer Research: 2020-present
• American Heart Journal Plus: 2020-present
• Scientific Sessions Abstract reviewer/grader:
• American College of Cardiology 2021Advisory Groups:
• President Elect Medical Staff, JFK Hospital, 2012-2013
• Chief of Staff, JFK Medical Center, 2014- 2015.
• Credentials Committee Chairman, JFK Hospital, 2012-2013
• Medical Executive Committee, JFK Hospital, 2004-2005, 2012-Present
• Board of Trustees, JFK Medical Center, 2012-2015
• Chairman Peer Review JFK Medical Center, 2016-2017
• Cardio-Vascular Co-Management Group, Governance Board member, Good Samaritan Medical Center.2013-2014

  COMMITTEE SERVICE:

  International:
• International Cardio Oncology Society: Education Committee 2020-present.
  G-COR (Global Cardio-Oncology Registry): Executive committee, Scientific committee, Disparities in Cardio-Oncology Committee. 2021-present
• National:
• American College of Cardiology: Cardio-oncology Leadership Council. April 2020-2023.
• American College of Cardiology: Co-Chair Cardio Oncology Advocacy Work Group. 2020-2023.
• American College of Cardiology: Cross-sections Advocacy Committee. 2021-present.
• COIN (Cardio-Oncology innovation network): Steering committee. 2021-present
  Regional/State/Florida:
• Chair, Cardio-Oncology Committee, Florida Chapter American College of Cardiology. 2018-present.
• Board of Directors, Florida Chapter American College of Cardiology. 2019-present.

See publications for Diego Sadler, MD.

(Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)

Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.

To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists receive or have the right to receive royalties or (iv) its physicians/ scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.

As of 4/9/2024, Dr. Sadler has reported no financial relationship with industry that is applicable to this listing. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by Cleveland Clinic. To learn more about Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.

Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers' discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias.

* Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.